China approves first commercial brain-computer implant

China's National Medical Products Administration approved Neuracle Medical Technology's NEO implant for commercial use, which FierceBiotech and Medical Device Network describe as the first invasive brain-computer interface cleared for sale beyond clinical trials. The device was developed with researchers at Tsinghua University and has been added to China's national health insurance system.

NEO is an epidural implant: eight electrodes rest on the dura mater, the brain's protective membrane, rather than penetrating cortical tissue as Neuralink's threads do. A coin-sized, wireless unit transmits power and data through an external magnetic coil, and the procedure takes roughly 90 minutes. The surface placement lowers risks of hemorrhage, glial scarring, and long-term signal degradation, but it also yields lower-resolution neural signals, placing more weight on decoding algorithms that translate activity into control of an external robotic glove.

For engineers building decoders and safety-monitoring systems, a commercially approved surface BCI validates a lower-risk path to market and creates a real population of long-term users whose data will test signal stability over time. The trade-off between surgical safety and signal fidelity is now a deployed-product question, not only a research one.

Independent, peer-reviewed outcomes and post-market safety data will determine whether the approval translates into durable clinical benefit. The competitive framing against Neuralink, which remains in FDA-supervised trials, is secondary to whether surface-based decoding holds up across many patients and months of use.